164
Participants
Start Date
May 15, 2014
Primary Completion Date
November 25, 2016
Study Completion Date
December 14, 2021
Everolimus
10mg dose
Exemestane
Fixed dose at 25mg
BI 836845
1000 mg, recommended dose per Phase Ib part. Human monoclonal antibody. Dose escalation in Phase Ib. 2 dose levels (high or low) depending on the dose cohort explored
Taipei Veterans General Hospital, Taipei
Brussels - UNIV UZ Brussel, Brussels
Wilhelminenspital, Vienna
Brussels - UNIV Saint-Luc, Brussels
Edegem - UNIV UZ Antwerpen, Edegem
UZ Leuven, Leuven
Centre Hospitalier Universitaire de Liège, Liège
Liège - HOSP St-Joseph, Liège
CHU UCL Namur - Site De Sainte-Elisabeth, Namur
Charleroi - HOSP Grand Hôpital de Charleroi, Charleroi
Medical University of Graz State Hospital - University Hospital Graz, Graz
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
National Taiwan University Hospital, Taipei
National Cancer Center, Goyang
INS Paoli-Calmettes, Marseille
Ctr Cario, Plerin Sur Mer
HOP Jean Minjoz, Besançon
Hospital Arnau de Vilanova, Lleida
MD Anderson Cancer Center Madrid, Madrid
Hospital Ramón y Cajal, Madrid
Hospital Clínico San Carlos, Madrid
Hospital Universitario 12 de Octubre, Madrid
Taichung Veterans General Hospital, Taichung
Hospital Virgen del Rocío, Seville
CTR Catherine de Sienne, Nantes
Hospital Clínico de Valencia, Valencia
HOP Européen G. Pompidou, Paris
INS Curie, Paris
St. Vincent's University Hospital, Dublin
Maastricht University, Maastricht
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Hospital Vall d'Hebron, Barcelona
Hospital Clínic de Barcelona, Barcelona
Centrummottagningen, Stockholm
Ninewells Hospital & Medical School, Dundee
St Bartholomew's Hospital, London
Freeman Hospital, Newcastle upon Tyne
Lead Sponsor
Boehringer Ingelheim
INDUSTRY